R&D pipeline

1.Development Stage and Region

Region Clinical Study
Phase 3
NDA Approved
Japan

SJP-0125
<Glaucoma,OH>

SJP-0135
<Glaucoma,OH>

Azithromycin
<Infection,
Perioperative sterilization>

 
Outside of Japan

SJP-0035
<Dry eye>
United States

   

2.Product Information

DrugDosage FormPropertyIndication
Azithromycin Topical ophthalmic solution Antibiotics Ocular infections,
Perioperative sterilization
SJP-0125 Topical ophthalmic solution Combination ophthalmic solution Glaucoma,
Ocular hypertension
SJP-0135 Topical ophthalmic solution Combination ophthalmic solution Glaucoma,
Ocular hypertension
SJP-0035 Topical ophthalmic solution Novel mechanism of action Dry eye

3.Additional Information

AzithromycinIt is a macrolide antimicrobial ophthalmic solution, which enhances the retention of medical agent due to its strong viscosity, and reduces the number of instillations.